STAT March 22, 2023
Paul J. Hastings

As a five-time biotech CEO, I’ve guided my companies through recessions, supply chain disruptions, Wall Street volatility, even a global pandemic.

Yet nothing quite prepared me for the news on Thursday, March 9, that my cell therapy company’s ability to make payroll could be jeopardized by the mother of all bank runs unfolding at Silicon Valley Bank. More than $42 billion was withdrawn in a single day after venture capitalist Peter Thiel and others yelled “fire” in a crowded chat room and told their portfolio companies to divest.

This, I confess, was uncharted territory for me. Fortunately, leaders at the Federal Deposit Insurance Corp. reached out to investor advisers and acted in swift, coordinated fashion to declare a systemic risk...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder
This Biotech Startup Aims To Speed Up Drug Testing On Animals
Scientists reveal new method that could reduce waste from drug manufacturing
ETH develops AI algorithm for drug discovery based on 3D protein surface
Pharma Pulse 4/26/24: 20 States Select Direct Care Workforce Enhancement Programs by HHS, Do Assigned Roles in Clinical Trials Affect Patient-Reported Outcomes? & more

Share This Article